PharmacoEconomics & Outcomes News 585 - 22 Aug 2009

Untapped markets offer largerewards

Current markets for arthritis, prostate cancer and drugdevice combinations are expected to grow while thedyslipidemia market shrinks, according to recentlyreleased reports from Decision Resources, and Researchand Markets.

Proportionally, the arthritis treatment drug market inBrazil is poised to be the largest winner, with a projectedgrowth of over 55% between 2008 and 2013, bringingtotal market value to more than $US315 million.1 The2008 market was led by tumour necrosis factor-alphainhibitors Humira [adalimumab] and Remicade[infliximab], despite holding a combined patient share of2%.

Drug device combinations (a vendible combination ofdrugs and medical devices) are further projected toshow compound annual market growth of 11.8% overthe next five years, primarily due to untapped marketpotential.2 Similarly, the significant unmet need fortherapies which target hormone-refractory metastasesfrom prostate cancer is expected to be filled by 2018,capturing more than one third of the overall prostatecancer market in France, Germany, Italy, Japan, Spain,the UK, and the US.3 Several agents, including thetherapeutic cancer vaccine sipuleucel-T [Provenge], areexpected to fuel this $US2 billion growth.

During the very same time frame the dyslipidemiadrug market in these countries is expected to shrink by$US4 billion, due to generic erosion of key statins suchas atorvastatin and rosuvastatin, whose US patentsexpire in 2010 and 2016, respectively.4 Opportunity stillexists in this market to develop treatments for thegrowing number of mixed dyslipidemia cases.1. Decision Resources. Brazil’s Rheumatoid Arthritis Drug Market Will Grow

$115 Million by 2013. Media Release : 20 Jul 2009. Available from: URL:http://www.decisionresources.com.

2. Research and Markets. Research and Markets: Drug and Device Combination2009-2014 - Current Market Has a Potential of US$10.6 Billion, a Growth of15% CAGR over the Past Two Years. Media Release : 14 Jul 2009. Availablefrom: URL: http://www.researchandmarkets.com.

3. Decision Resources Inc. Driven by Launch of Emerging Therapies, OverallProstate Cancer Drug Market Will Increase by $2 Billion Through 2018. MediaRelease : 27 Jul 2009. Available from: URL: http://www.decisionresources.com.

4. Decision Resources Inc. Through 2018, Generic Erosion of Key Statins Such asLipitor and Crestor Will Reduce the Dyslipidemia Drug Market by $4 Billion.Media Release : 21 Jul 2009. Available from: URL: http://www.decisionresources.com.

801108569

1

PharmacoEconomics & Outcomes News 22 Aug 2009 No. 5851173-5503/10/0585-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved